CXCR4 antagonist BKT140 combined with TKI was found to overcome the protection of bone marrow stroma and reduce the growth of CML cells both in vitro and in vivo (97). Here, CXCR4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.